As we explore the utility of cytokine modulation in heart failure (HF), it is imperative that the biological rationale of potential therapeutic agents be fully understood. A recent editorial 1 questioned the rationale for the use of Enbrel (etanercept) as an effective tumor necrosis factor (TNF) antagonist as described in a recent study by Deswal et al in patients with heart failure. 2 The following comments will attempt to clarify the mechanism and the rationale for etanercept therapy in this population of patients.
